Filter by
Filter by
Multivariate normal tissue complication probability models for rectal and bladder morbidity in prostate cancer patients treated with proton therapy
The study included rectum and bladder DVHs, 2D rectal dose maps and relevant patient/treatment characteristics from 1151 prostate cancer cases treated with PT...
Comparative Analysis of 5-Year Clinical Outcomes and Patterns of Failure of Proton Beam Therapy (PBT) versus Intensity-Modulated Radiotherapy (IMRT) for Prostate Cancer in the Postoperative Setting
This case-matched study analyzed 260 prostate cancer patients including 65 treated with PBT and 195 IMRT. At a median follow-up of 59 months, biochemical...
Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.
A study reported toxicity of 526 localized prostate cancer patients treated with proton therapy and demonstrated the safety of HFPT for localized PCa patients...
Biochemical Results, Toxicity, Patient QoL After Delivery of Dose-Escalated Image Guided PT for Prostate Cancer
A large series of 1327 localized prostate cancer patients reported 5-year biochemical control rate, toxicity and patient-reported quality of life after proton...
Prostate Cancer
Jason Efstathiou gives an overview of protons for prostate cancer. He covers the clinical potential, the available and comparative data, and the future...
Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
This study compared the bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26 collected in 262...